Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | KHK | P50053 | 8/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456229 | 0.87 | KHK (0.59) | HPGDCYP1A2CYP2C19SMN1; SMN2CYP2D6 | |
| SCHEMBL25680549 | 0.86 | KHK (0.55) | HPGDCYP1A2CYP2C19SMN1; SMN2CYP2D6 | |
| SCHEMBL30073688 | 0.86 | KHK (0.55) | HPGDMAPK1HSD17B10KHKPDE10A | |
| SCHEMBL23592027 | 0.86 | KHK (0.55) | HPGDMAPK1HSD17B10KHKPDE10A | |
| SCHEMBL23775096 | 0.86 | KHK (0.55) | HPGDMAPK1HSD17B10KHKPDE10A | |
| SCHEMBL25680555 | 0.83 | KHK (0.55) | HPGDMAPK1HSD17B10KHKKDM4E | |
| SCHEMBL23592969 | 0.83 | KHK (0.55) | HPGDCYP2C19MAPK1HSD17B10KHK | |
| SCHEMBL25240191 | 0.81 | KHK (0.51) | HPGDMAPK1KHKL3MBTL1MAPT | |
| SCHEMBL23592941 | 0.81 | KHK (0.56) | HPGDMAPK1HSD17B10KHKKDM4E | |
| SCHEMBL23592026 | 0.81 | KHK (0.51) | HPGDMAPK1HSD17B10KHKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479829-B2 | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| CN-115361999-B | 2- [ 2-Methylazetidin-1-yl ] -4-phenyl-6- (trifluoromethyl) -pyrimidine compounds | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-115361999-B | 2- [ 2-Methylazetidin-1-yl ] -4-phenyl-6- (trifluoromethyl) -pyrimidine compounds | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4103280-B1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | LILLY CO ELI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20230167087-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| EP-4103280-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115361999-A | 2- [ 2-methylazetidin-1-yl ] -4-phenyl-6- (trifluoromethyl) -pyrimidine compounds | 伊莱利利公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115361999-A | 2- [ 2-methylazetidin-1-yl ] -4-phenyl-6- (trifluoromethyl) -pyrimidine compounds | 伊莱利利公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2021162943-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167087-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | SLC5A2, GOT2, FABP1 | HPGD 734/4885CYP1A2 192/4885CYP2C19 587/4885 |
| US-12479829-B2 | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds | SLC5A2, GOT2, FABP1 | HPGD 734/4885CYP1A2 192/4885CYP2C19 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.